–13 years after ApoA-1 Milano sparked excitement the novel HDL therapy appears to be dead. After 13 years and despite the efforts of 3 separate companies, the novel cholesterol therapy known as ApoA-1 Milano appears to be dead. On Monday afternoon the Medicines Company announced that it had discontinued development of the drug and would…
Early Look: New Methods To Enhance Cholesterol Efflux
November 5, 2012 by Leave a Comment
Although clinical trials of HDL-boosting CETP inhibitors have so far failed to produce positive results, many other avenues of HDL-related research remain active. A glimpse at the very early phases of two intriguing lines of research in this area was offered on Monday at the AHA. Apo A-1 is thought to be the key HDL…
Recent Comments